Therapeutics
Procedures concerned with the remedial treatment or prevention of diseases.
Subtype terms (88)
More specific conditions that are subtypes of Therapeutics in the MeSH hierarchy.
- Acoustic Stimulation
- Airway Management
50 drugs (43 approved, 7 experimental)
- Apitherapy
- Balneology
- Bed Rest
2 drugs experimental
- Behavior Control
- Biological Therapy
8 drugs (6 approved, 2 experimental)
- Blood Component Removal
2 drugs (1 approved, 1 experimental)
- Bridge Therapy
- Catheterization
11 drugs (10 approved, 1 experimental)
- Cautery
- Chronotherapy
- Climatotherapy
- Clinical Protocols
- Cognitive Enhancement
- Combined Modality Therapy
- Complementary Therapies
1 drug experimental
- Conservative Treatment
- Contraindications
- Cosmetic Techniques
5 drugs (4 approved, 1 experimental)
- Cryotherapy
4 drugs (2 approved, 2 experimental)
- Decompression
1 drug approved
- Drainage
4 drugs (3 approved, 1 experimental)
- Drug Therapy
223 drugs (149 approved, 74 experimental)
- Electric Stimulation Therapy
3 drugs (1 approved, 2 experimental)
- Electroporation Therapies
- Emergency Treatment
1 drug approved
- Feeding Methods
- Fetal Therapies
- Gender-Affirming Procedures
- Genomic Medicine
- Glycemic Control
62 drugs (24 approved, 38 experimental)
- Hemodilution
7 drugs (6 approved, 1 experimental)
- Hemostatic Techniques
1 drug experimental
- Host-Directed Therapy
- Hygiene
6 drugs (3 approved, 3 experimental)
- Hyperthermia, Induced
- Insufflation
1 drug approved
- Intubation
51 drugs (45 approved, 6 experimental)
- Ischemic Postconditioning
- Ischemic Preconditioning
6 drugs (4 approved, 2 experimental)
- Laser Therapy
5 drugs (1 approved, 4 experimental)
- Leeching
- Lithotripsy
2 drugs approved
- Maggot Debridement Therapy
- Magnetic Field Therapy
- Mechanical Thrombolysis
- Non-Medical Prescribing
- Nutrition Therapy
12 drugs (5 approved, 7 experimental)
- Obesity Management
1 drug experimental
- Olfactory Training
- Organ Sparing Treatments
- Orthokeratologic Procedures
- Orthopedic Procedures
34 drugs (31 approved, 3 experimental)
- Orthoptics
- Pain Management
55 drugs (41 approved, 14 experimental)
- Patient Care
- Patient Care Bundles
- Patient Isolation
4 drugs experimental
- Phototherapy
6 drugs (4 approved, 2 experimental)
- Physical Therapy Modalities
9 drugs (6 approved, 3 experimental)
- Placebos
37 drugs (25 approved, 12 experimental)
- Precision Medicine
16 drugs (9 approved, 7 experimental)
- Preservation, Biological
- Prosthesis Fitting
- Punctures
1 drug approved
- Radiofrequency Therapy
3 drugs approved
- Radiotherapy
93 drugs (57 approved, 36 experimental)
- Rehabilitation
12 drugs (5 approved, 7 experimental)
- Rejuvenation
3 drugs (2 approved, 1 experimental)
- Remission Induction
13 drugs (10 approved, 3 experimental)
- Renal Replacement Therapy
21 drugs (20 approved, 1 experimental)
- Reproductive Techniques
1 drug approved
- Respiratory Therapy
1 drug experimental
- Retreatment
1 drug experimental
- Rewarming
- Salvage Therapy
5 drugs approved
- Secondary Prevention
6 drugs (5 approved, 1 experimental)
- Self Care
- Sorption Detoxification
- Tertiary Prevention
- Theranostic Nanomedicine
2 drugs experimental
- Therapeutic Occlusion
- Therapies, Investigational
- Therapy, Computer-Assisted
- Therapy with Helminths
- Tobacco Use Cessation Devices
- Treatment Switching
Drugs by status
Phase 4 trials (30)
- ranibizumab
- berberine
- clozapine
- tofacitinib
- prednisone
- suvorexant
- probucol
- amoxicillin
- kunxian
- platelet-rich plasma
- memantine
- methimazole
- adalimumab
- immune globulin (human)
- ribavirin
- sodium oligo-mannurarate
- tocilizumab
- yunnan baiyao
- zolpidem
- methotrexate
- cilostazol
- clarithromycin
- isoniazid
- omeprazole
- tretinoin
- dalteparin
- interferon alpha-2b
- iguratimod
- tinzaparin
- jia-wei-xiao-yao-san
Phase 3 trials (21)
Phase 2 trials (37)
- azacitidine
- avatrombopag
- urea
- venetoclax
- coriolus versicolor
- cycloserine
- eltrombopag
- obinutuzumab
- gemcitabine
- imatinib
- lapatinib
- hydroxychloroquine
- insulin human
- pemetrexed
- carboplatin
- sitagliptin
- bevacizumab
- estradiol
- bortezomib
- nicotinamide
- triamcinolone
- rituximab
- cisplatin
- ivosidenib
- daratumumab
- sargramostim
- cytarabine
- mitoxantrone
- nilotinib
- dexamethasone
- +7 more
Phase 1 trials (5)